Antisense therapy to block the Kallikrein-kinin pathway in COVID-19: The ASKCOV randomized controlled trial.
Zampieri FG, Westphal GA, Santos MAD, Gomes SPC, Gomes JO, Negrelli KL, Santos RHN, Ishihara LM, Miranda TA, Laranjeira LN, Valeis N, Santucci EV, de Souza Dantas VC, Gebara O, Cohn DM, Buchele G, Janiszewski M, de Freitas FG, Dal-Pizzol F, de Matos Soeiro A, Berti IR, Germano A, Schettini DA, Rosa RG, Falavigna M, Veiga VC, Azevedo LCP, Damiani LP, Machado FR, Cavalcanti AB; BRICNet.
Zampieri FG, et al. Among authors: schettini da.
J Crit Care. 2024 Dec;84:154892. doi: 10.1016/j.jcrc.2024.154892. Epub 2024 Aug 3.
J Crit Care. 2024.
PMID: 39096659
Free article.
Clinical Trial.